Controlling acute bacterial maxillary sinusitis

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 10, 2002, Pages 1471-1479

  Bergogne Bérézin, Eugénie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

lactams; Acute maxillary sinusitis; Antibiotic therapy; Clarithromycin; Coamoxiclav; Levofloxacin; Moxifloxacin; Telithromycin

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACAMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; KETOLIDE; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN V; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNINDEXED DRUG;

ADENOVIRUS; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG USE; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; INFLUENZA VIRUS; MAXILLA SINUSITIS; MEDICAL DECISION MAKING; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NOSE SECRETION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAINFLUENZA VIRUS; PATHOGENICITY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOVIRUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SYMPTOM;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE; FLUOROQUINOLONES; HUMANS; MAXILLARY SINUS; SINUSITIS;

EID: 0036796330     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.10.1471     Document Type: Review

References (44)

1. PITKÄNRA A, HAYDEN F: Rhinoviruses: important respiratory pathogens. Trends in clinical practice. The Finnish Medical Society Duodecim, Ann. Med. (1998) 30:529-537.
2. WINTHER B, GWALTNEY JM JR: Acute and chronic sinusitis. In: Respiratory Infections: Diagnosis and Management 3rd edn. Pennington J (Ed.), Raven Press, New York, NY (1994) Ch. 7:125-136.
3. REYNOLDS HY: Normal and defective respiratory host defenses. In: Respiratory Infections: Diagnosis and Management 3rd edn. Pennington J (Ed.), Raven Press, New York, NY (1994) Ch. 1:1-34.
4. KANKAM CG, SALLIS R: Acute sinusitis in adults. Difficult to diagnose, essential to treat. Postgrad. Med. (1997) 102:253-258.
5. KLOSSEK JM, FERRIE JC: Radiology and pathologies of the paranasal cavities. Rev. Laryngol. Otol. Rhinol. (1999) 120:167-172.
6. LOW DE, DESROSIERS M, MCSHERRY J et al: A practical guide for the diagnosis and treatment of acute sinusitis. Can. Med. Assoc. J. (1997) 156(Suppl. 6):S1-S14.
7. Recommandations AFSSAPS: Antibiothérapie par voie générale en pratique courante: sinusite aiguë de l'adulte. Antibiotiques (2002) 2:127-129.
8. WILLIAMS JW, SIMEL DL: Does this patient have sinusitis? Diagnosing acute sinusitis by history and physical examination. JAMA (1993) 270:1242-1246.
9. HUESTON WJ, EBERLEIN C, JOHNSON D, MAINOUS AG: Criteria used by clinicians to differentiate sinusitis from viral upper respiratory tract infection. Fam. Pract. (1998) 46:487-492.
10. SOKOL W: Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. (2001) 111(Suppl. 9A):19S-24S.
11. STOLL D, DUTKIEWICZ J, BOINEAU F, DUMON T: Bactériologie rhinosinusienne. Rev. Laryngol. Otol. Rhinol. (1996) 117:179-182.
12. STOLL D: Inflammation rhinosinusienne aiguë. Presse Med. (2001) 30(39-40 Pt 2):33-40.
13. VAN CAUWENBERGE P, INGELS K: Effects of viral and bacterial infection on nasal and sinus mucosa. Acta Otolaryngol. (1996) 116:316-321.
14. FELMINGHAM D, GRÜNEBERG RN: The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. (2000) 45(2):191-203.
15. PENTTILA M, SAVOLAINEN S, KIUKAANNIEMI H, FORSBLOM B, JOUSIMIES-SOMEER H: Bacterial findings in acute maxillary sinusitis - European study. Acta Otolaryngol. Suppl. (1997) 529:165-168.
16. BAX R, BYWATER R, CORNAGLIA G et al.: Surveillance of antimicrobial resistance - what, how and whither? Clin. Microbiol. Infect. (2001) 7:316-325.
17. MASTERTON RG: Surveillance studies: how can they help the management of infection? J. Antimicrob. Chemother. (2000) 46(Suppl T2):53-58.
18. BERGOGNE-BÉRÉZIN E, VALLÉE E: Pharmacokinetics of antibiotics in respiratory tissues and fluids. In: Respiratory Infections: Diagnosis and Management; 3rd edn. Pennington JE (Ed.), Raven Press, New York, NY (1994) Ch. 35:366-387.
19. DINIS PB, MONTEIRO MC, MARTINS ML, SILVA N, GOMES A: Sinus tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope (2000) 110:1050-1054.
20. BERGOGNE-BÉRÉZIN E: Tissue distribution of macrolide antibiotics. In: Bryskier AJ, Butzler JP, Neu HC, Tulkens PM (Eds), Macrolides. Chemistry, Pharmacology and clinical uses. Arnette Blackwell Publishers, Paris (1993) Ch. 33:451-484.
21. OGAWA H, FUJISAWA T, KAZUYAMA Y: Isolation of Chlamydia pneumoniae from middle ear aspirates of otitis media with effusion: a case report J. Infect. Dis. (1990) 162:1000-1001.
22. LISTER PD, SANDERS CC: Pharmacodynamics of levofloxacin and ciprofloxacin. Clin. Microb. Infect. (1998) 4:264-269.
23. VALLÉE E, AZOULAY-DUPUIS E, POCIDALO JJ, BERGOGNE-BÉRÉZIN E: Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob. Agents Chemother. (1992) 36:1412-1417.
24. MURBACH V, BRONNER S, LINGER L et al: Bêta-lactamases et inhibiteurs: existence d'un effet post-inhibiteur de bêta-lactamases de l'acide clavulanique sur H. influenzae, K. pneumoniae et E. coli. Antibiotiques (2001) 3:35-41.
25. BRONNER S, POMPEI D, ELKHAILI H, DHOYEN N, MONTEIL H, JEHL F: Ex vivo 12h bactericidal activity of oral coamoxiclav (1.125g) against β-lactamase producing Haemophilus influenzae. J. Antimicrob. Chemother. (2001) 48:501-506.
26. DRUSANO GL, CRAIG WA: Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J. Chemother. (1997) 9:38-44.
27. DE BOCK GH, DEKKER FW, STOLK J, SPRINGER MP, KIEVIT J, VAN HOUWELINGEN JC: Antimicrobial treament in acute maxillary sinusitis: a meta-analysis. J. Clin. Epidemiol. (1997) 50:881-890.
28. LINDBEAK M, HORTJDAHL P, JONHSEN UL: Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. Br. Med. J. (1996) 313:325-329.
29. VAN BUCHEM FL, KNOTTNERUS JA, SCHRINEMAEKERS VJJ, PEETERS MF: Primary-care based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet (1997) 349:683-687.
30. FAGNAN, LJ: Acute sinusitis: a cost-effective approach to diagnosis and treatment. Am. Fam. Physician, (1998) 58:1795-1802.
31. BERT F, LAMBERT-ZECHOVSKY N: Microbiology of nosocomial sinusitis in intensive care unit patients. J. Infect. (1995) 31:5-8.
32. BARZA M: Pharmacokinetics and efficacy of the new quinolones in infections of the eye, ear, nose and throat. Rev. Infect. Dis. (1988) 10(Suppl.1):S241-S247.
33. BRYSKIER A: Les alternatives thérapeutiques dans les infections respiratoires: place de la lévofloxacine. Antibiotiques (2000) 2:35-51.
34. SYDNOR TA, KOPP EJ, ANTHONY KE, LOCOCO JM, KIM SS, FOWLER CL: Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann. Allergy Asthma Immunol. (1998) 80:357-362.
35. ADELGLASS J, DEABATE CA, MCELVAINE P, FOWLER CL, LOCOCCO J, CAMPBELL T: Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol, Head Neck Surg. (1999) 120:320-327.
36. LASKO B, LAU CY, SAINT-PIERRE, REDDINGTON JL, MARTEL A ANSTEY RJ: Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. J. Int. Med. Res. (1998) 26(6):281-291.
37. TILLOTSON GS, WATSON SJ: Moxifloxacin: from A (Antimicrobial) to Z (zwitterion) - a new 8-methoxyquinolone. Antibiotiques (2000) 2:185-194.
38. BAZ MN, JANNETTI W, VILLANUEVA C et al: The efficacy and tolerabilty of moxifloxacin compared to trovafloxacin in the treatment of acute sinusitis. Today's Therap. Trends (1999) 17:303-319.
39. KLOSSEK J: Moxifloxacin versus trovafloxacin in the treatment of acute sinusitis. 3rd European Congress on Chemotherapy, Madrid, Spain (7 - 10 May 2000) Abstract M178.
40. PERRY CM, ORMROD D, HURST M, ONRUST SV. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs (2002) 62:169-207.
41. BERGOGNE-BEREZIN E: Resistance and new strategies. The other new molecules. Presse Med. (2000) 37:240-245
42. BARMAN BALFOUR JA, FIGGITT DP: Telithromycin. Drugs (2001) 61:815-831.
43. ROOR K, BRUNSWIG-PATSCHNER C et al.: Efficacy and tolerability of a new ketolide antimicrobial, telithromycin (HMR 3647) for treatment of acute sinusitis. 40th ICAAC. Toronto, Canada (16 - 20 September 2000) Abstract 2243.
44. GUAY DR: Review of ceftidoren, an advanced-generation, broad spectrum oral cephalosporin. Clin. Ther. (2001) 23:1924-1937.